ArticleMedical care2016
Comparison of SEER Treatment Data With Medicare Claims.
Article in Medical care, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 299 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
299 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Role of surgery to the primary tumor in metastatic anaplastic thyroid carcinoma: pooled analysis and SEER-based study.Journal of cancer research and clinical oncology · 2023Pooled it
- Prostate Cancer: Community Education and Disparities in Diagnosis and Treatment.The oncologist · 2021Pooled it
- After the Maps: Assessing Longitudinal Neighborhood Change After Historical Redlining with Present-Day Breast Cancer Survival.Journal of urban health : bulletin of the New York Academy of Medicine · 2026Article
- Association of Travel Time With Definitive Prostate Cancer Treatment: A United States Registry Cohort Study.Cancer medicine · 2026Article
- Frailty and low utilization of curative-intent surgical resection in nonmetastatic pancreatic cancer.JNCI cancer spectrum · 2026Article
- Reliance on topographical coding alone may overestimate survival in pancreatic ductal adenocarcinoma.Surgery in practice and science · 2026Article
- Type 2 Diabetes Risk Among Older Asian, Native Hawaiian and Pacific Islander Patients With Head and Neck Cancer in the United States.Cancer medicine · 2026Article
- Association of the Affordable Care Act With Receipt of Guideline-Concordant Adjuvant Chemotherapy for Colon and Non-Small Cell Lung Cancer.Cancer medicine · 2026Article
- Article
- Assessing Concordance of Cancer Registry Data and Electronic Health Record Data in Metastatic Cancer: a Cohort Study of Patients with Colorectal Liver Metastasis in a U.S. Integrated Health System.Cancer epidemiology · 2026Article
- Effect of Primary Breast Surgery on Prognosis in Breast Cancer Patients Presenting with Isolated Bone Metastases.Cancers · 2026Article
- Cause-specific mortality in a population-level cohort of pancreatic cancer patients following chemotherapy: A SEER-based study.Medicine · 2026Article
- Immigration and Social Factors, Tumor Stage, and Risk of Contralateral Breast Cancer in Asian American and Hispanic Women.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2026Article
- Agreement between Surveillance, Epidemiology, and End Results- and Medicare Claims-Derived Uterine Cancer Treatment Data.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2026Article
- Population-Based Associations of Body Mass Index and Treatments Received for Breast Cancer in a Rural, Midwestern State.Cancer medicine · 2026Article
- Adjuvant chemotherapy for completely resected stage IB-IIA non-small cell lung cancer according to the AJCC 8th edition staging system: a real-world retrospective cohort study based on the SEER database.Translational lung cancer research · 2026Article
- Historical redlining, breast cancer survival, and the mediating and modifying role of contemporary neighborhood socioeconomic conditions.American journal of epidemiology · 2026Article
- Association of Guideline-Concordant Care with Survival in Adolescent and Young Adult Patients with Germ Cell Tumors.Journal of adolescent and young adult oncology · 2026Article
- Treatment Delays and Survival Divides: Race, Sex, and Early-Onset Colorectal Cancer Disparities.Cancer research communications · 2026Article
- Follow-up-dependent calendar-period associations with cardiac mortality after lung cancer radiotherapy: a competing-risks SEER analysis.Open medicine (Warsaw, Poland) · 2026Article
239 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundThe population-based Surveillance, Epidemiology, and End Results (SEER) registries collect information on first-course treatment, including surgery, chemotherapy, radiation therapy, and hormone therapy. However, the SEER program does not release data on chemotherapy or hormone therapy due to uncertainties regarding data completeness. Activities are ongoing to investigate the opportunity to supplement SEER treatment data with other data sources.
methodsUsing the linked SEER-Medicare data, we examined the validity of the SEER data to identify receipt of chemotherapy and radiation therapy among those aged 65 and older diagnosed from 2000 to 2006 with bladder, female breast, colorectal, lung, ovarian, pancreas, or prostate cancer and hormone therapy among men diagnosed with prostate cancer at age 65 or older. Treatment collected by SEER was compared with treatment as determined by Medicare claims, using Medicare claims as the gold standard. The κ, sensitivity, specificity, positive predictive values, and negative predictive values were calculated for the receipt of each treatment modality.
resultsThe overall sensitivity of SEER data to identify chemotherapy, radiation, and hormone therapy receipt was moderate (68%, 80%, and 69%, respectively) and varied by cancer site, stage, and patient characteristics. The overall positive predictive value was high (>85%) for all treatment types and cancer sites except chemotherapy for prostate cancer.
conclusionsSEER data should not generally be used for comparisons of treated and untreated individuals or to estimate the proportion of treated individuals in the population. Augmenting SEER data with other data sources will provide the most accurate treatment information.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.